Analysis of Depression and Anxiety Scores Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Adults With Cystic Fibrosis

Autor: Harish Pudukodu, Margret Z. Powell, Agathe Ceppe, Scott H. Donaldson, Jennifer L. Goralski, Nathaniel A. Sowa

Publikováno v: The Clinical Respiratory Journal, Vol 18, Iss 9, Pp n/a-n/a (2024)

ABSTRACT Objective Elexacaftor/tezacaftor/ivacaftor (E/T/I) has provided life‐changing pharmacotherapy for many people with cystic fibrosis (CF), but conflicting literature exists regarding the effect on mental health. While some reports suggest E/

Externí odkaz: https://doaj.org/article/b8c0da60930648538af2d110c36c6b2f

Liberalism's Last Hurrah : The Presidential Campaign of 1964

Autor: Robert H Donaldson

Marked by sharp ideological divisions over civil rights, Vietnam, and federal power, the 1964 presidential campaign between Democrat Lyndon Johnson and Republican Barry Goldwater proved a watershed election in American history. Although Johnson defea

Repetitive transcranial magnetic stimulation (rTMS) in autism spectrum disorder: protocol for a multicentre randomised controlled clinical trial

Autor: Adam J Guastella, Ian B Hickie, Jeffrey M Craig, Karen Barlow, Andrew J O Whitehouse, Karen Caeyenberghs, Helen Heussler, Paul B Fitzgerald, Cherrie Galletly, Peter G Enticott, Melissa K Licari, Nigel C Rogasch, Christel M Middeldorp, Scott R Clark, Ann-Maree Vallence, Kelsie A Boulton, Gail A Alvares, Hakuei Fujiyama, Melissa Kirkovski, Natalie T Mills, Nicole J Rinehart, Peter H Donaldson, Talitha C Ford, Natalia Albein-Urios, Soukayna Bekkali

Publikováno v: BMJ Open, Vol 11, Iss 7 (2021)

Introduction There are no well-established biomedical treatments for the core symptoms of autism spectrum disorder (ASD). A small number of studies suggest that repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation tec

Externí odkaz: https://doaj.org/article/5f55135337104a468eb341ac1dc03a1d

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Autor: Nicole Mayer-Hamblett, Felix Ratjen, Renee Russell, Scott H Donaldson, Kristin A Riekert, Gregory S Sawicki, Katherine Odem-Davis, Julia K Young, Daniel Rosenbluth, Jennifer L Taylor-Cousar, Christopher H Goss, George Retsch-Bogart, John Paul Clancy, Alan Genatossio, Brian P O'Sullivan, Ariel Berlinski, Susan L Millard, Gregory Omlor, Colby A Wyatt, Kathryn Moffett, David P Nichols, Alex H Gifford, Margaret Kloster, Katie Weaver, Claire Chapdu, Jing Xie, Michelle Skalland, Melita Romasco, Sonya Heltshe, Noah Simon, Jill VanDalfsen, Anna Mead, Rachael Buckingham, Kathy Seidel, Nikita Midamba, Laurel Couture, Brooke Zappone Case, Wendy Au, Elsie Rockers, Diane Cooke, Amber Olander, Irene Bondick, Miya Johnson, Lisya VanHousen, Boris Nicholson, Michelle Parrish, Dion Roberts, Jillian Head, Jessica Carey, Lindsay Caverly, Joy Dangerfield, Rachel Linnemann, Jason Fullmer, Chelsea Roman, Peter Mogayzel, Deanne Reyes, Amy Harmala, Jerimiah Lysinger, Jonathan Bergeron, Isabel Virella-Lowell, Perry Brown, Lejla Godusevic, Alicia Casey, Lauren Paquette, Thomas Lahiri, Julie Sweet, Scott Donaldson, Joshua Harris, Shelia Parnell, Sylvia Szentpetery, Deborah Froh, Erica Tharrington, Manu Jain, Rachel Nelson, Sharon Kadon, Gary McPhail, Kimberly McBennett, Tia Rone, Elliott Dasenbrook, Dave Weaver, Terri Johnson, Karen McCoy, Raksha Jain, Maria Mcleod, Mary Klosterman, Preeti Sharma, Amy Jones, Gary Mueller, Rachel Janney, Jennifer Taylor-Cousar, Mary Cross, Jordana Hoppe, James Cahill, Zubin Mukadam, Jill Finto, Karen Schultz, Silvia Delgado Villalta, Alexa Smith, Susan Millard, Thomas Symington, Gavin Graff, Diane Kitch, Don Sanders, Misty Thompson, Tahuanty Pena, Mary Teresi, Jennifer Gafford, David Schaeffer, Joel Mermis, Lawrence Scott, Hugo Escobar, Kristen Williams, Dana Dorman, Brian O'Sullivan, Ryan Bethay, Zoran Danov, Kat Turbeville, Jimmy Johannes, Angelica Rodriguez, Bridget Marra, Robert Zanni, Ronald Morton, Terri Simeon, Andrew Braun, Nicole Dondlinger, Julie Biller, Erin Hubertz, Nicholas Antos, Laura Roth, Joanne Billings, Catherine Larson, Priya Balaji, John McNamara, Tammy Clark, Rebecca Griffith, Nancy Martinez, Sabiha Hussain, Halina Malveaux, Marie Egan, Catalina Guzman, Joan DeCelie-Germana, Susan Galvin, Adrienne Savant, Nicole Falgout, Patricia Walker, Teresa Demarco, Emily DiMango, Maria Ycaza, Julie Ballo, Pornchai Tirakitsoontorn, Daniel Layish, Desiree Serr, Floyd Livingston, Sherry Wooldridge, Carlos Milla, Jacquelyn Spano, Rebecca Davis, Okan Elidemir, Subramanyam Chittivelu, Ashley Scott, Sarah Alam, Daniel Dorgan, Matt Butoryak, Daniel Weiner, Harmony Renna, Colby Wyatt, Brendan Klein, Anne Stone, Meg Lessard, Michael S. Schechter, Barbara Johnson, Steven Scofield, Theodore Liou, Jane Vroom, Kathryn Akong, Marissa Gil, Legna Betancourt, Jonathan Singer, Ngoc Ly, Courtney Moreno, Moira Aitken, Teresa Gambol, Ronald Gibson, Allison Lambert, Joan Milton, Sarah Smith, Deanna Green, Diana Hodge, Christopher Fortner, Mary Forell, Rachel Karlnoski, Kapil Patel, Cori Daines, Elizabeth Ryan, Rodolfo Amaro-Galvez, Elizabeth Dohanich, Alison Lennox, Zachary Messer, Holly Hanes, Kay Powell, Deepika Polineni

Publikováno v: The Lancet Respiratory Medicine. 11:329-340

Reducing treatment burden is a priority for people with cystic fibrosis, whose health has benefited from using new modulators that substantially increase CFTR protein function. The SIMPLIFY study aimed to assess the effects of discontinuing nebulised

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a610bdf6f80f9f99b6e9a399c3e8c0aa
https://doi.org/10.1016/s2213-2600(22)00434-9

Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI

Autor: Sarah Jane Schwarzenberg, Phuong T. Vu, Michelle Skalland, Lucas R. Hoffman, Christopher Pope, Daniel Gelfond, Michael R. Narkewicz, David P. Nichols, Sonya L. Heltshe, Scott H. Donaldson, Carla A. Frederick, Andrea Kelly, Jessica E. Pittman, Felix Ratjen, Margaret Rosenfeld, Scott D. Sagel, George M. Solomon, Michael S. Stalvey, John P. Clancy, Steven M. Rowe, Steven D. Freedman

Publikováno v: Journal of Cystic Fibrosis. 22:282-289

Elexacaftor/tezacaftor/ivacaftor (ETI) improves pulmonary disease in people with cystic fibrosis (PwCF), but its effect on gastrointestinal symptoms, which also affect quality of life, is not clear.PROMISE is a 56-center prospective, observational st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e79d99c628d03d00d355a597ce8b465
https://doi.org/10.1016/j.jcf.2022.10.003